OCUGEN INC. - COMMON

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

22 Feb 2022 20:43:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

22 Feb 2022 15:02:55 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

18 Feb 2022 17:12:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

18 Feb 2022 16:25:00 By Nasdaq GlobeNewswire

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

15 Feb 2022 06:25:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

27 Jan 2022 08:25:00 By Nasdaq GlobeNewswire

Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety

24 Jan 2022 06:12:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 Jan 2022 17:12:00 By Nasdaq GlobeNewswire

COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

12 Jan 2022 05:43:00 By Nasdaq GlobeNewswire

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

08 Jan 2022 17:27:00 By Nasdaq GlobeNewswire